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Abstract: Two new p-cymene ruthenium(II) complexes containing as additional 
ligands N-methylpiperazine ([(η6-p-cymene)RuCl2(CH3NH(CH2)4NH)]PF6, com-
plex 1) or vitamin K3-thiosemicarbazone ([(η6-p-cymene)RuCl2(K3tsc)], com-
plex 2) were synthesized starting from [(η6-p-cymene)2RuCl2]2 and the cor-
responding ligand. The complexes were characterized by elemental analysis, IR, 
electronic absorption and NMR spectroscopy. The X-ray crystal structure de-
termination of complex 1 revealed “piano-stool” geometry. The differences in 
the cytotoxic activity of the two complexes are discussed in terms of the ligand 
present. 
Keywords: ruthenium(II) complexes; p-cymene; K3-thiosemicarbazone; N-me-
thylpiperazine; cytotoxic activity. 
INTRODUCTION 
The field of organoruthenium complexes has been widely explored in recent 
years with regard to biological activity as well as catalytic activity of these 
complexes.1–5 Many of these compounds are soluble in water and display cyto-
toxicity to cancer cells, including cisplatin-resistant cancer cells.6,7 
Vitamin K3, menadione, (2-methylnaphthalene-1,4-dione), is a fat-soluble 
vitamin and it is necessary for the production of prothrombin and five other 
blood clotting factors in humans. It also regulates bone calcification.8 In addition, 
it was found that vitamin K3, as well as its water-soluble derivative, menadione 
sodium bisulfite, has significant antitumor activity in vitro and in vivo.9 
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On the other hand, thiosemicarbazones play an important role in research 
related to biological activity.10 These ligands form complexes with metals and 
the influence of chelatation on antitumor activity has been very intensively in-
vestigated.11,12 Thiosemicarbazones are the ligands of choice because thiosemi-
carbazones themselves exhibit antineoplastic activity. One of the most effective 
thiosemicarbazone is triapine (3-aminopyridine-2-carboxaldehyde thiosemicarba-
zone).13,14 This compound acts as a very strong iron chelator and, consequently, 
inhibits ribonucleotide reductase (RR) activity.15 The role of RR in the rate of 
replication of cancer cells has been well established.16 
Hitherto, the thiosemicarbazone derivative of vitamin K3 was used in the 
preparation of complexes with metals, such as Mn(II), Co(II), Ni(II), Cu(II), 
Zn(II) and Au(I).17−19 It should be mentioned that the ruthenium chemistry of 
thiosemicarbazones has received little attention, especially concerning their po-
tential antitumor activity. Ru(II) formed several complexes with thiosemi-
carbazones and some of them showed cytotoxic activity.20−22 In addition, re-
cently a lot of other ruthenium complexes containing the arene moiety have been 
synthesized and some of them have been evaluated for activity both in vitro and 
in vivo.23−26 Some of the prepared complexes of the type [(η6-arene)-
RuCl(X)(Y)] showed cytotoxic activity to cisplatin-resistant cell lines. Prelimi-
nary structure–activity data showed that the hydrophobic arene group, the dia-
mine NH group and the Cl leaving group may all play important roles in the 
anticancer activity of these complexes.27 
In this paper, the characterization of two newly synthesized complexes of 
Ru(II) with p-cymene, which contain additional ligands K3tsc or N-methylpipe-
razine, is described. 
EXPERIMENTAL 
Materials 
Menadione sodium bisulfite (MSB), thiosemicarbazide, α-terpinene and N-methylpipe-
razine were commercially available and used without further purification. MSB thiosemicar-
bazone (NaK3tsc) was prepared by treating thiosemicarbazide with menadione sodium bisul-
fite in an ethanol–water mixture using a published procedure.17 
The complex [(η6-p-cymene)2RuCl2]2 was prepared following a published protocol.28 
Synthesis of the complexes 
Synthesis of [(η6-p-cymene)RuCl2(CH3NH(CH2)4NH)]PF6 (1). A solution of N-methyl-
piperazine (0.07 ml, 0.50 mmol) in dry methanol (5.0 ml) was added to a solution of [(η6-p- 
-cymene)2RuCl2]2 (120 mg, 0.20 mmol) in dry methanol (10 ml). The resulting mixture was 
stirred 2 h in dark. Orange solution was then concentrated to half volume and 250 mg 
(1.5 mmol) of NH4PF6 was added. The light orange product that appeared during night was 
filtered off, washed with ethanol, and ether. Yield: 92.2 mg (42 %). 
Synthesis of [(η6-p-cymene)RuCl2(K3tsc)] (2). A solution of K3tsc (220 mg, 0.50 mmol) 
in dry methanol (5.0 ml) was added to a solution of [(η6-p-cymene)2RuCl2]2 (120 mg, 
0.20 mmol) in dry methanol (10 ml). The resulting mixture was stirred for 3 h. The obtained 
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orange solution was then concentrated to half volume and left at 4 °C overnight. The light 
orange product was filtered off, washed with methanol and then diethyl ether. Yield: 166 mg 
(67 %). 
Physical measurements 
Elemental analyses were carried out with an Elemental Vario EL III microanalyser. The 
infrared spectra were recorded on a Perkin–Elmer FTIR 31725X spectrometer using KBr pel-
lets (4000–400 cm-1). The electronic spectra were obtained using a GBC UV/Vis Cintra 40 
spectrophotometer. The NMR spectra were recorded on a Varian Gemini 200 instrument. The 
chemical shifts for the 1H and 13C spectra are referenced to the residual 1H and 13C present in 
deuterated dimethyl sulfoxide. 
X-ray crystal structure determination 
A crystal of complex 1 suitable for an X-ray diffraction study was obtained by the slow 
diffusion of n-propanol into an aqueous solution of the complex. The data of complex 1 were 
collected with a CCD Oxford Xcalibur S (λ(MoKα) = 0.71073 Å) using the ω and ϕ scan 
modes at 130 K. Semi-empirical correction for absorption was performed with SCALE3 
ABSPACK.29 The structure was solved by direct methods.30 Structure refinement was per-
formed with SHELXL-97.31 All non-hydrogen atoms were refined anisotropically and the H 
atoms were located in ∆F and refined isotropically. Table I lists crystallographic details. The 
hydrogen atoms from the N-methylpiperazine ligand were placed at their calculated positions 
and refined using the riding model. The −6PF  anions are disordered as demonstrated by their 
larger-than-normal mean-square displacement parameters. The structural disorder of the −6PF  
anions explains the relatively high R factors. A disordered model for PF6 with split F-atom 
positions was introduced. The resultant thermal parameters were better than those without the 
split of the F-atom positions. Also, the split of the F-atom positions in three parts were exami-
ned. In addition, the latter refinement involved severe correlations and the resultant thermal 
parameters of the F-atoms were still unreasonable. Therefore, the split positions within the 
−
6PF  anion were introduced into the calculations and a least-squares refinement in the space 
group P21/c with disordered F-atoms was preferred with the present data. 
TABLE I. Crystal data, data collection and refinement parameters for 1 
Empirical formula C15H27Cl2N2RuF6P 
Formula weight, g mol-1 552.33 
Crystal system/space group monoclinic/P21/c 
a / Å 12.2534(7) 
b / Å 7.9458(16) 
c / Å 14.0359(8) 
β / ° 111.114(6) 
V / Å3 2082.2(2) 
Z  4 
ρ / g cm-3 1.762 
µ(MoKα) / mm-1 1.142 
F(000) 1112 
Scan range, ° 2.98 < θ < 25.51 
Reciprocal lattice segments h –14 → 14, 
 k –15 → 15, 
 l –17 → 16 
Reflections collected 3860 
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Table I. Continued 
Reflections independent [Rint] 2198 [0.078] 
Data/restraints/parameters 3860/0/236 
Goodness-of-fit on F2 1.00 
R1, wR2 [I > 2σ(I)] 0.074, 0.183 
R1, wR2 (all data) 0.135, 0.209 
Largest differences peak and hole (e Å-3) 3.55 and –1.19 
Crystallographic data for the structural analyses of 1 have been deposited with the Cam-
bridge Crystallographic Data Centre, CCDC-658171. Copies of this information may be 
obtained free of charge from The Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK 
(Fax: +44 1223-336033; E-mail: deposit@ccdc.cam.ac.uk; http//www.ccdc.cam.ac.uk). 
Cytotoxicity assays 
Preparation of the drug solutions. Stock solutions of the investigated ruthenium com-
plexes were prepared in dimethyl sulfoxide (DMSO) at a concentration of 10 mM, filtered 
through a 0.22 µm Millipore filter before use and diluted with nutrient medium to various 
working concentrations. DMSO was used due to solubility problems. The nutrient medium 
was RPMI 1640 medium, without phenol red, supplemented with L-glutamine (3.0 mM), 
streptomycin (100 µg ml-1), penicillin (100 IU ml-1), 10 % fetal bovine serum (FBS) and 25 mM 
Hepes, was adjusted to pH 7.2 with bicarbonate solution. MTT, 3-(4,5-dimethylthiazol-2-yl)- 
-2,5-diphenyltetrazolium bromide was dissolved (5.0 mg ml-1) in phosphate buffer saline, 
pH 7.2, and filtered through a 0.22 µm Millipore filter before use. All reagents were products 
of Sigma Chemicals. 
Cell culture. Human cervix adenocarcinoma HeLa, malignant melanoma Fem-x and hu-
man breast carcinoma MDA-MB-361 and MDA-MB-453 cells were cultured as monolayers 
in the nutrient medium, while human myelogenous leukemia K562 cells were maintained as a 
suspension culture. The cells were grown at 37 °C in a 5.0 % CO2 humidified air atmosphere. 
For the growth of MDA-MB-361 and MDA-MB-453 cells and all subsequent experiments, 
the complete medium was enriched with 1.11 g dm-3 glucose. Peripheral blood mononuclear 
cells (PBMC) were separated from whole heparinized blood of a healthy volunteer by Lym-
phoprep (Nycomed, Oslo, Norway) gradient centrifugation. The interface cells, washed three 
times with Haemaccel (aqueous solution supplemented with 145 mM Na+, 5.1 mM K+, 6.2 mM 
Ca2+, 145 mM Cl- and 35 g dm-3 gelatin polymers, pH 7.4) were counted and resuspended in 
nutrient medium. 
Cell sensitivity analysis. HeLa (2,000 cells per well), Fem-x (2,000 cells per well), 
MDA-MB-361 (10,000 cells per well), and MDA-MB-453 cells (3,000 cells per well) were 
seeded into 96-well microtiter plates and 20 h later, after cell adherence, five different con-
centrations of the investigated compounds were added to the wells. The final concentrations 
were in the range from 12.5 to 200 µM. Only nutrient medium was added to the cells in the 
control wells. The investigated compounds were added to a suspension of leukemia K562 
cells (3,000 cells per well) 2 h after cell seeding, in the same final concentrations as applied to 
the HeLa and Fem-x cells. All experiments were performed in triplicate. Nutrient medium 
with the corresponding concentrations of the compounds but void of cells was used as the 
blanks. PBMC were seeded (150,000 cells per well) into nutrient medium or into nutrient 
medium enriched with (5.0 µg ml-1) phytohaemaglutinin (PHA, Welcome Diagnostics, En-
gland) in 96-well microtiter plates and 2 h later the investigated compounds were added to the 
wells, in triplicate, at five final concentrations, except to the control wells where nutrient 
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medium only was added to the cells. Nutrient medium with the corresponding concentrations 
of the compounds but void of cells was used as the blanks. 
Determination of target cell survival. Cell survival was determined by the MTT test ac-
cording to the method of Mosmann32 modified by Ohno and Abe33 and Drakulić et al.,34 72 h 
after drug addition. The concentration IC50 of the investigated compounds which diminished 
the survival of the target cells by 50 % was assessed from graphs of cell survival vs. 
concentration of the investigated compound. 
RESULTS AND DISCUSSION 
Synthesis of the complexes 
The neutral [(η6-p-cymene)RuCl2(K3tsc)] (2) and cationic [(η6-p-cymene)-
RuCl2(CH3NH(CH2)4NH)]PF6 (1) organoruthenium complexes were obtained 
by reaction of K3tsc and N-methylpiperazine, respectively, with [(η6-p-cymene)2-
RuCl2]2 at ambient temperature (Scheme 1). Complex 1 is well soluble in water, 
ethanol (methanol) and DMSO, whereas complex 2 is less soluble in water and 
ethanol. 
 
Scheme 1. Preparation of complexes 1 and 2. 
Thiosemicarbazones usually coordinate with a metal ion either in the neutral 
thione form or, after deprotonation, in the N,S ligand chelating mode. The diver-
sity of coordination can be further increased by the introduction of an additional 
donor site into the thiosemicarbazone through the donor atom of carbonyl com-
pounds.11 
X-ray diffraction study of 1 
The selected bond and angle parameters are listed in Table II. The molecule 
adopts the usual three-legged “piano-stool” arrangement generally found in 
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[M(η6-arene)L3] units (Fig. 1). Complex 1 is the first structurally characterized 
mononuclear complex of the [Ru(η6-p-cymene)Cl2L] type with the Ru atom bon-
ded directly to a heterocyclic amine. 
TABLE II. Selected bond lengths (Å) and angles (°) for complex 1 
Ru1–Cga 1.674(5) Ru1–Cl2 2.401(3) 
Ru1–Cl1 2.420(2) Ru1–N1 2.161(8) 
Cg–Ru1–Cl1 127.15(16) Cg–Ru1–Cl2 127.29(17) 
Cg–Ru1–N1 135.0(2) Cl1–Ru1–Cl2 87.63(9) 
Cl1–Ru1–N1 82.2(2) Cl2–Ru1–N1 80.6(2) 
aThe abbreviation Cg is the centroid of the η6-arene ligand 
Fig. 1. ORTEP presentation of [(η6-p- 
-cymene)RuCl2(CH3NH(CH2)4NH)]+ 
cation in crystals of 1. Displacement 
ellipsoids are plotted at the 50 % pro-
bability level and H atoms are shown as 
small spheres of arbitrary radii. 
The distance between the metal and the arene centroid, 1.674(5) Å is very 
similar to that observed in other ruthenium(II) complexes of the [Ru(η6-p-cyme-
ne)Cl2L] class (L/bond distance = dimethylamine/1.666; sec-butylamine/1.663– 
–1.664; p-toluidine/1.637 Å).35−37 Similarly to the mentioned complexes, the 
angles between the "legs" of the stool are slightly less than 90°, due to steric 
hindrance of the arene ligand. The Ru–N distance (2.161(8) Å) is comparable 
with the same bond distance in [RuCl2(η6-p-cymene)(NH(CH3)2)] (2.165 Å), but 
it is significantly longer than those found in compounds of the same type,36,37 
indicating a relatively weaker bond. 
An interesting feature of this structure is the protonation of both N atoms of 
the N-methylpiperazine ring, probably originating from NH4PF6. 
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Characterization of the complexes 
The analytic and spectroscopic data of the synthesized complexes are as follows. 
[(η6-p-cymene)RuCl2(CH3NH(CH2)4NH)]PF6 (1). Anal. Calcd. for C15H27-
Cl2N2PF6Ru: C, 32.62; H, 4.93; N, 5.07. Found: C, 32.82; H, 4.93; N, 4.94. IR 
(KBr, cm−1): 3331–3435, 1630, 1467, 841. 1H-NMR (199.97 MHz, DMSO-d6, δ, 
ppm): 8.14 (1H, s, NH), 5.79, 5.51 (4H, m, η6−C6H4), 3.06 (4H, t, HN(CH2)2), 
2.86 (4H, m, CH3N(CH2)2), 2.30 (3H, s, NCH3), 2.20 − 2.00 (4H, m, CH(CH3)2, 
η6−C6H4−CH3), 1.20 (6H, d, CH(CH3)2). 13C-NMR (50 MHz, DMSO-d6, δ, 
ppm): 106.60 (C-1), 100.31 (C-4), 86.58 (C-3,5), 85.73 (C-2,6), 51.46 (C-12,14), 
45.60 (C-11,13), 43.14 (C-15), 30.18 (C-7), 21.70 (C-8,9), 18.07 (C-10). Elec-
tronic spectrum (H2O) [λmax / nm (εmax / 103 dm3 mol−1 cm−1)]: 386 (sh) (0.4), 
306 (sh) (0.8), 255 (1.8). 
[(η6-p-cymene)RuCl2(K3tsc)] (2). Anal. Calcd. for C22H26Cl2N3NaO4S2Ru: 
C, 40.31; H, 4.00; N, 6.41; S, 9.80. Found: C, 40.41; H, 4.12; N, 6.92; S, 10.35; 
IR (KBr, cm−1): 3363–3437, 1682, 1619, 1224, 1031, 762. 1H-NMR (199.97 MHz, 
DMSO-d6, δ, ppm): 10.88 (1H, s, N4H), 9.70, 9.06 (2H, s, N3H2), 8.52 (1H, d, 
PhH, tsc), 7.86 (1H, d, PhH, tsc), 7.57 (2H, q, PhH, tsc), 5.79, 6.28 (4H, m, 
η6−C6H4), 3.80 (1H, d, Ha, tsc), 2.87 (1H, t, Hb, tsc), 2.15 (4H, m, CH(CH3)2, 
η6−C6H4−CH3), 1.51 (3H, s, CH3, tsc), 1.23 (6H, s, CH(CH3)2). 13C-NMR (50 MHz, 
DMSO-d6, δ, ppm): 194.94 (C-2), 179.21 (C-9), 144.70 (C-6), 138.19 (C-10), 
133.05 (C-12), 132.96 (C-15), 129.17 (C-11), 126.42 (C-14), 124.88 (C-13), 
107.98 (C-17), 102.32 (C-20), 85.67 (C-19,21), 83.60 (C-18,22), 65.50 (C-8), 
56.25 (C-17), 35.27 (C-7), 30.52 (C-23), 22.26 (C-26), 21.33 (C-16), 18.76 (C-24), 
17.98 (C-25). Electronic spectrum (H2O/EtOH, 50/50) [λmax / nm (εmax / 103 
dm3 mol−1 cm−1)]: 275 (sh) (15.3), 244 (19.4), 223 (19.3). 
NMR spectra 
The 1H-NMR spectra of both complexes displayed characteristic resonances 
which can be attributed to the coordination of p-cymene, as well as thiosemicar-
bazone, or N-methylpiperazine. In both complexes the signals corresponding to 
the phenyl ring of cymene moiety are at δ 5.79 and 5.51 (1) and at 6.26 and 5.79 
(2) ppm. The signals which can be assigned to the two methyl groups of the 
isopropyl groups are at 1.20 (1) and 1.23 (2) ppm. The methyl group of the p-cy-
mene moiety displays a signal at around δ 2.10 ppm for both complexes. The 
signals assigned to the CH group of the isopropyl group were centered at δ 2.10 
(1) and 2.15 (2) ppm. Hydrogen resonances due to the CH2 groups of the pipe-
razine ring are located at 2.72–2.97 ppm, appearing as a triplet of triplets 
((CH2)2NCH3), whereas those attached to the NH part of the heterocycle appear 
as a triplet centered at 3.06 ppm. The resonance confirming the protonation of the 
piperazine nitrogen is located at 8.14 ppm. In complex 2, the signals corres-
ponding to the phenyl ring of the coordinated K3tsc are at δ 7.57 (q), 7.86 (d) and 
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8.52 (d). Two resonances at 3.80 and 2.87 ppm were assigned to the two dia-
stereotropic protons of the CH2 group of the thiosemicarbazone moiety. A signal 
that can be assigned to the methyl group of thiosemicarbazone is at δ 1.51 (s) ppm. 
Two resonances at 9.06 and 9.70 ppm were assigned to the two protons of the 
N3H2 chain, whereas the proton of the azomethine nitrogen appears at 11.88 ppm. 
The 13C-NMR spectrum of complex 1 shows upfield shifts (51.46 (C-2,6), 45.60 
(C-3,5), 43.14 (C-7)) for the piperazine part of the molecule comparing to free 
piperazine (56.29 (C-2,6), 46.75 (C-3,5) and 45.67 (C-7)), due to coordination 
via the unsubstituted N-4 nitrogen. In the spectrum of complex 2, a slight upfield 
shift of C-2 was observed as a consequence of S-metallation, while no remar-
kable shifts of the other carbon atoms were observed. 
Infrared spectra 
The spectrum of the free ligand, K3tsc, was compared with those of the 
complexes to confirm its coordination to metal ion. The ν(CS) vibrations suffer a 
negative shift from 1278 (L) to 1232 cm−1 (2). Also, the ν(CN) vibration of the 
C2–N4 bond is slightly shifted to lower frequencies due to the partial multiplicity 
of this bond after coordination. The peaks at 1690 cm−1 in the spectrum of the 
free ligand due to ν(C=O) vibrations and at 1639 cm−1 due to ν(CN) vibrations 
of C6–N5 remained unchanged in the complex, confirming the non-coordination 
of oxygen and the azomethine nitrogen to the metal ion. 
This study showed that in complex 2, K3tsc acts as a neutral monodentate 
ligand, which is coordinated to the metal ion via the sulfur atom. 
UV/Vis spectra 
The complexes exhibit intense absorption in the visible region which can be 
ascribed to high intensity metal-to-ligand charge transfer bands which interfere 
with the expected d–d transitions, as is observed in low-spin d6 ruthenium(II) 
complexes.38 In general, complexes 1 and 2 exhibit two well resolved bands. The 
bands at higher wavelengths can be ascribed to a Ru(4dπ) → π∗(NH) MLCT 
transition, whereas the bands at lower wavelengths are attributable to intraligand 
transitions or a combination of MLCT bands and intraligand transitions. 
Cytotoxicity assays 
The in vitro cytotoxicity of complexes 1 and 2 was determined by an MTT- 
-based assay. The complexes were tested for cytotoxic activity on tumor cell 
lines: human adenocarcinoma HeLa, human myelogenous leukemia K562, human 
malignant melanoma Fem-x, human breast carcinoma MDA-MB-361 and MDA-
-MB-453 cells and on normal immunocompetent cells, i.e., on human peripheral 
blood mononuclear PBMC cells non-stimulated and stimulated for proliferation 
with phytohaemaglutinin (PHA). The data are given in Table III and Fig. 2. 
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TABLE III. IC50 (µM) for 72 h of action of the investigated compounds on various tumor cells 
and on non-stimulated PBMC and PBMC stimulated with PHA, determined by the MTT test 
Compound Tumor cell 
1 2 
HeLa >200 62.50±3.54 
K562 >200 71.26±4.22 
Fem-x >200 152.10±5.18 
MDA-MB-361 >200 101.84±6.54 
MDA-MB-453 >200 62.46±5.98 
PBMC-PHA Not detected 61.10±1.12 





Fig. 2. Survival of tumor cells, determined by 
the MTT test after 72 h of continuous action 
of the applied concentrations of the investigated 
complexes 1 (– –) and 2 (– –), as a function 
of the concentration of the tested compounds. 
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Complex 1 exerted low activity against all the selected cell lines (IC50 > 200 µM, 
Table III and Fig. 2) as determined by the MTT test. This result is consistent with 
the characteristics of ruthenium compounds which are generally less cytotoxic 
than platinum compounds. One of two ruthenium complexes that is under clinical 
investigations, trans-[HInd][RuCl4(Ind)2] (Ind = indazole; KP1019) is only mo-
derately cytotoxic to cancer cells,39 whereas the other complex, trans-[HIm]-
[RuCl4(DMSO)(Im)] (Im = imidazole; NAMI-A) is relatively non-toxic to pri-
mary cancer cells, but exhibits antimetastatic activity.40 
Complex 2 showed low to moderate activity with IC50 = 152.10 µM for 
Fem-x and IC50 = 101.84 µM for the slowly proliferating MDA-MB-361 cells. 
Against HeLa, K562 and the rapidly proliferating MDA-MB-453 cell lines, com-
pound 2 exerted a moderate dose dependent antiproliferative action, with IC50 
values of 62.50, 71.26 and 62.46 µM, respectively. Complex 2 was more active 
against the normal control PBMC, with IC50 = 61.10 µM for non-stimulated 
resting PBMC and IC50 = 40.38 µM for PBMC stimulated by PHA. Results from 
this work are in accordance with many publications which deal with antitumor 
activity of metal complexes of thiosemicarbazones13,14,22 and of antileukemia 
potency of thiosemicarbazones.41,42 In addition, this compound acted toxically, 
especially to PBMC which were stimulated for proliferation. This indicates that 
the mentioned complex might also have a capability for the suppression of auto-
immune diseases. Further investigations in this direction need to be performed. 
CONCLUSIONS 
Two new organoruthenium complexes were synthesized and characterized. 
The results from this work showed that the ruthenium complex containing vita-
min K3-thiosemicarbazone as the organic part exerted its maximal cytotoxic acti-
vity against immunocompetent cells stimulated for proliferation. The higher 
activity of this complex compared with the complex containing N-methylpipe-
razine is probably related with the presence of vitamin K3-thiosemicarbazone, 
itself active. In addition, the obtained data indicate that complex 2 could be further 
studied regarding its promising action for the control not only of malignant 
diseases, but also for the control of autoimmune diseases. 
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И З В О Д  
СИНТЕЗА, СТРУКТУРНА КАРАКТЕРИЗАЦИЈА И ЦИТОТОКСИЧНА АКТИВНОСТ ДВА 
НОВА ОРГАНОРУТЕНИЈУМ(II) КОМПЛЕКСА 
САЊА ГРГУРИЋ-ШИПКА1, MOHAMED AL.ARBI M. ALSHTEWI1, ДЕЈАН ЈЕРЕМИЋ1, ГОРАН Н. КАЛУЂЕРОВИЋ2, 
SANTIAGO GÓMEZ-RUIZ3, ЖЕЉКО ЖИЖАК4, ЗОРИЦА JУРАНИЋ4 и ТИБОР Ј. САБО1 
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Синтетисана су два нова p-цимен-рутенијум(II) комплекса који садрже као додатне 
лиганде N-метилпиперазин ([(η6-p-cimen)RuCl2(CH3NH(CH2)4NH)]PF6, комплекс 1) и вита-
мин K3-тиосемикарбазон ([(η6-p-cimen)RuCl2(K3tsc)], комплекс 2). Оба нова комплекса доби-
јена су полазећи од [(η6-p-cimen)2RuCl2]2 комплекса и одговарајућег лиганда. Комплекси су 
окарактерисани елементалном анализом, ИЦ, електронско-апсорпционом и НМР спектро-
скопијом. Рендгено–структурна анaлиза комплекса 1 показала је „piano-stool“ геометрију. У 
зависности од присутног лиганда дискутована је разлика у цитотоксичној активности ова два 
добијена комплекса. 
(Примљено 27. децембра 2007, ревидирано 4. марта 2008) 
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